# PDUFA dates January 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-01

> 137 FDA catalysts are dated in January 2026, including 9 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in January 2026?

PDUFA dates in January 2026: tividenofusp (DNLI) on January 5, 2026; Tab-cel (tabelecleucel, ATRA) on January 10, 2026; Sanofi (SNY) on January 13, 2026; FILSPARI (sparsentan, TVTX) on January 13, 2026; ZYCUBO (CUTX-101, FBIO) on January 14, 2026; Aquestive Therapeutics, Inc. (AQST) on January 31, 2026; and 3 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-01)

Source: Press release filed with the SEC (EX-99), accession 0001714899-25-000146, https://www.sec.gov/Archives/edgar/data/1714899/000171489925000146/exhibit991pressrelease7720.htm (retrieved 2026-11-12). Last confirmed 2026-02-26. Cite: https://sec-api.dev/fda-calendar/2026-01#answer

## PDUFA dates in January 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| January 5, 2026 | Denali Therapeutics Inc. | DNLI | tividenofusp |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000146/exhibit991pressrelease7720.htm) |
| January 10, 2026 | Atara Biotherapeutics, Inc. | ATRA | Tab-cel (tabelecleucel) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/d66575dex991.htm) |
| January 13, 2026 | Sanofi | SNY |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm) |
| January 13, 2026 | Travere Therapeutics, Inc. | TVTX | FILSPARI (sparsentan) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/aex991_2025q4xearningsprex.htm) |
| January 14, 2026 | Fortress Biotech, Inc. | FBIO | ZYCUBO (CUTX-101) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465926061233/fbio-20260331x10q.htm) |
| January 31, 2026 | Aquestive Therapeutics, Inc. | AQST |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aqst-20260109.htm) |
| January 31, 2026 | Aquestive Therapeutics, Inc. | AQST | Anaphylm™ (dibutepinephrine) | Type 1 allergic reactions | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aquestivepressrelease-fi.htm) |
| January 31, 2026 | Pharming Group N.V. | PHAR |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000043/pharminggroupannouncesusfd.htm) |
| January 31, 2026 | Pharming Group N.V. | PHAR | Joenja® (leniolisib) |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000049/a2025q3pressrelease.htm) |

## All catalysts in January 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 2026 | [Neurosteroid enantiomer primary completion](https://sec-api.dev/pdufa/neurosteroid-enantiomer) | OGEN | Mild Traumatic Brain Injury, Concussion | delayed | "NCT06870240 (A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2026-01-01 (ESTIMATED); Lead Sponsor Oragenics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06870240)) |
| January 5, 2026 | [SULANDA® (surufatinib) trial start](https://sec-api.dev/pdufa/surufatinib) | HCM | metastatic pancreatic ductal adenocarcinoma | completed | "Hong Kong, Shanghai & Florham Park, NJ — Monday, January 5, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma ("PDAC") in China." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000002/hcm-20260105xex99d1.htm)) |
| January 5, 2026 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "CorMedix announces preliminary, unaudited financial results for Q4 and FY 2025, including net revenue of approximately $127 million and $310 million, for Q4 2025 and FY 2025, respectively, FY 2025 Pro Forma net revenue(1) of approximately $400 million, and Q4 2025 adjusted EBITDA(2) in the range of $77 million to $81 million." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390026002350/ea027214901ex99-1_cormedix.htm)) |
| January 5, 2026 | [DA-1726 topline data readout](https://sec-api.dev/pdufa/da-1726) | MTVA | Obesity | completed, positive | "On January 5, 2026, we announced positive topline data of Phase 1 MAD Part 2 non-titrated 48 mg Cohort 5 clinical trial of DA-1726." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926004337/tm2528002-19_424b4.htm)) |
| January 5, 2026 | [Tividenofusp PDUFA date](https://sec-api.dev/pdufa/tividenofusp) | DNLI |  | scheduled | "•FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000146/exhibit991pressrelease7720.htm)) |
| January 5, 2026 | [Descartes-08 primary completion](https://sec-api.dev/pdufa/descartes-08) | RNAC | Myasthenia Gravis, Generalized | completed | "NCT04146051 (Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-05 (ACTUAL); Lead Sponsor Cartesian Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04146051)) |
| January 5, 2026 | [Botvymo® (botensilimab) primary completion](https://sec-api.dev/pdufa/botensilimab) | AGEN | Metastatic Pancreatic Ductal Adenocarcinoma | completed | "NCT05630183 (A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-05 (ACTUAL); Lead Sponsor Agenus Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05630183)) |
| January 5, 2026 | [Tev-48574 dose regimen a primary completion](https://sec-api.dev/pdufa/tev-48574-dose-regimen-a) | TEVA | Crohn Disease; Colitis, Ulcerative | completed | "NCT05668013 (A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-05 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05668013)) |
| January 5, 2026 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Immunoglobulin A Nephropathy; IgAN | completed | "NCT06291376 (Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-05 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06291376)) |
| January 6, 2026 | [BMB-101 topline data readout](https://sec-api.dev/pdufa/bmb-101) | DRUG | drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy | completed, positive | "NEW YORK CITY, January 6, 2026 -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) ("Bright Minds" or the "Company"), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating BMB-101, a selective 5-HT2C biased agonist, in adult patients with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1827401/000206075526000005/ex991-drugnr.htm)) |
| January 6, 2026 | [ALUMIS INC. topline data readout](https://sec-api.dev/companies/alms/catalysts) | ALMS | moderate-to-severe plaque psoriasis | completed, positive | "On January 6, 2026 we announced positive topline results from our Phase 3 ONWARD1 and ONWARD2 global Phase 3, multi-center, randomized, double-blind placebo-controlled clinical trials, evaluating envu in patients with PsO." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)) |
| January 6, 2026 | [ATI-052 interim data readout](https://sec-api.dev/pdufa/ati-052) | ACRS |  | completed, positive | "WAYNE, Pa., January 6, 2026 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced positive interim results from the first-in-human Phase 1a single (SAD) and multiple ascending dose (MAD) trial of its anti-TSLP/IL-4Rα bispecific antibody ATI-052." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926001076/acrs-20260106xex99d1.htm)) |
| January 6, 2026 | [Praliciguat trial start](https://sec-api.dev/pdufa/praliciguat) | AKBA | biopsy-confirmed FSGS, a rare kidney disease, and dosed the first patient in December 2025 | completed | "Although we performed additional work to manufacture product for clinical trials than originally anticipated before we could initiate the trial for praliciguat, on January 6, 2026, we announced that the first patient was dosed in a Phase 2 clinical trial in the U.S. However, even though the clinical trial has started, we may be unsuccessful in developing praliciguat." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm)) |
| January 6, 2026 | [Irritable bowel syndrome with constipation (ibs-c) participants (lin-md-63 and lin-md-64 completers) topline data readout](https://sec-api.dev/pdufa/irritable-bowel-syndrome-with-constipation-ibs-c-participants-lin-md-63-and-lin-) | ABBV | Irritable Bowel Syndrome With Constipation; Functional Constipation | completed | "NCT04166058 (Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-01-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04166058?tab=results)) |
| January 6, 2026 | [LINZESS® (linaclotide) topline data readout](https://sec-api.dev/pdufa/linaclotide) | ABBV | Functional Constipation | completed | "NCT05760313 (A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-01-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05760313?tab=results)) |
| January 6, 2026 | [BLINCYTO® (blinatumomab) primary completion](https://sec-api.dev/pdufa/blinatumomab) | AMGN |  | completed | "NCT06054113 (Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-06 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06054113)) |
| January 6, 2026 | [ALXN1850 primary completion](https://sec-api.dev/pdufa/alxn1850) | AZN | Hypophosphatasia | completed | "NCT06079359 (Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-06 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079359)) |
| January 7, 2026 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526006266/d52798dex991.htm)) |
| January 7, 2026 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000003/exhibit991-q425certainfina.htm)) |
| January 7, 2026 | [YCANTH (cantharidin) trial start](https://sec-api.dev/pdufa/cantharidin) | VRCA | common warts in December 2025, and Company expects to initiate the second Phase 3 study | completed | "On January 7, 2026, the Company announced that the first patient was dosed in December 2025 in the first trial (COVE-2) of our global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529dex991.htm)) |
| January 7, 2026 | [MRT-8102 interim data readout](https://sec-api.dev/pdufa/mrt-8102) | GLUE |  | completed, positive | "On January 7, 2026, the Company announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1826457/000119312526005420/glue-20260107.htm)) |
| January 7, 2026 | [NTX-253 trial start](https://sec-api.dev/pdufa/ntx-253) | ADXN |  | completed | "Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1574232/000117184326000110/exh_991.htm)) |
| January 7, 2026 | [Atuliflapon primary completion](https://sec-api.dev/pdufa/atuliflapon) | AZN | Asthma | completed | "NCT05251259 (Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-07 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05251259)) |
| January 7, 2026 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | completed | "NCT05477524 (An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-07 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05477524)) |
| January 7, 2026 | [LY3549492 primary completion](https://sec-api.dev/pdufa/ly3549492) | LLY | Obesity; Overweight | completed | "NCT06683508 (A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-07 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06683508)) |
| January 7, 2026 | [Experimental: ltg-001 high dose primary completion](https://sec-api.dev/pdufa/experimental-ltg-001) | LTGO | Acute Pain; Postoperative Pain Control | completed | "NCT07102459 (An Efficacy and Safety Study of LTG-001 Following Abdominoplasty): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-07 (ACTUAL); Lead Sponsor Latigo Biotherapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07102459)) |
| January 8, 2026 | [STANDARD BIOTOOLS INC. earnings report](https://sec-api.dev/companies/lab/catalysts) | LAB |  | completed | "BOSTON, Mass., January 8, 2026 -- Standard BioTools Inc. (NASDAQ: LAB) ("Standard BioTools" or the "Company") today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1162194/000119312526006996/lab-ex99_1.htm)) |
| January 8, 2026 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "CHICAGO, IL; January 8, 2026 - Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000004/pressreleaseissuedbyxerisb.htm)) |
| January 8, 2026 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira expects to report its complete financial results for the fourth quarter and full-year 2025, along with the company's financial guidance, later in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828026001335/pcrx-2025revenuepressrelea.htm)) |
| January 8, 2026 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "The Company expects to report its fourth quarter and full-year 2025 financial results in late February 2026 which will contain additional information required for a more complete understanding of the Company's financial position and results of operations as of and for the year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526006998/cgem-ex99_1.htm)) |
| January 8, 2026 | [Lacutamab primary completion](https://sec-api.dev/pdufa/lacutamab) | IPHA | Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides/Sezary Syndrome | completed | "NCT03902184 (IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-08 (ACTUAL); Lead Sponsor Innate Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03902184)) |
| January 8, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 2 Diabetes; Obesity | completed | "NCT06037252 (A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-08 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06037252)) |
| January 8, 2026 | [Taltz (ixekizumab) primary completion](https://sec-api.dev/pdufa/ixekizumab) | LLY | Psoriasis; Obesity | completed | "NCT06588283 (Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-08 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588283)) |
| January 9, 2026 | [IMCIVREE® (setmelanotide) earnings report](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | completed | "® 4 Continued Growth in IMCIVREE Global Sales ~10% increase in number of patients globally on reimbursed therapy 11% Q4 2025 preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) QoQ increase from Q3 2025** 68% of Q4 2025 revenue from U.S. 69% of FY 2025 revenue from U.S. $57M* Q4 2025 ~ $194M FY 2025 ~ The Company plans to report fourth quarter and full year 2025 financial results in February * Preliminary, unaudited Q4 2025 revenue from vials shipped to U.S. specialty pharma in excess of vials dispensed to patients is approximately $1.7M; **Reminder: During Q3 2025, Rhythm recorded a one-time $3.2 million charge following a final agreement with French authorities for reimbursement for IMCIVREE for POMC/LEPR and BBS." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/exhibit992rytm_january20.htm)) |
| January 9, 2026 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company's 2025 financial results is completed and the company reports its full financial results for the fourth quarter and full-year 2025, which is anticipated to occur in early March 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056226000003/ex991010926.htm)) |
| January 9, 2026 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore will report its final and complete fourth-quarter and full-year 2025 financial results in late February 2026, and the actual results could be different from these preliminary unaudited financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036126000780/ef20062561_ex99-1.htm)) |
| January 9, 2026 | [BRUKINSA® (zanubrutinib) primary completion](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed | "NCT04116437 (Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-09 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04116437)) |
| January 10, 2026 | [Tab-cel (tabelecleucel) PDUFA date](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | completed, complete response letter | "Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/d66575dex991.htm)) |
| January 11, 2026 | [Vyjuvek (beremagene geperpavec) earnings report](https://sec-api.dev/pdufa/beremagene-geperpavec) | KRYS |  | completed | "PITTSBURGH, January 11, 2026 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company's strategic vision to drive the next stage of growth of its rare disease business." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000008/jpm2026preannouncementprex.htm)) |
| January 11, 2026 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "* The preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in February 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000162828026001755/alny2026q1exhibit991.htm)) |
| January 11, 2026 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000003/exel20260111exhibit991.htm)) |
| January 11, 2026 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/d947742dex991.htm)) |
| January 12, 2026 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "PRINCETON, N.J., Jan. 12, 2026 -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced preliminary select financial results for full year 2025, provided full year 2026 financial guidance, and outlined its strategic priorities for continued growth." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000005/anip-20260112xexx991.htm)) |
| January 12, 2026 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "The Company will present at the 44th Annual J.P. Morgan Healthcare Conference today at 4:30 p.m. PT, and expects to announce complete full year 2025 financial results and provide a corporate update in February." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/aex991_2025q4xearningsprex.htm)) |
| January 12, 2026 | [Adaptive Biotechnologies Corp earnings report](https://sec-api.dev/companies/adpt/catalysts) | ADPT |  | completed | "SEATTLE, January 12, 2026 - (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478320/000119312526009840/d29941dex991.htm)) |
| January 12, 2026 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "This announcement is not a comprehensive statement of Axsome's financial results and is subject to completion of Axsome's financial closing procedures." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526009744/axsm-ex99_1.htm)) |
| January 12, 2026 | [ABCL635 trial start](https://sec-api.dev/pdufa/abcl635) | ABCL |  | completed | "On January 12, 2026, AbCellera Biologics Inc. (the "Company"), issued a press release announcing the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000003/abcl-20260112.htm)) |
| January 12, 2026 | [ELUTIA INC. earnings report](https://sec-api.dev/companies/elut/catalysts) | ELUT |  | completed | "Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708527/000110465926002742/elut-20260112xex99d1.htm)) |
| January 12, 2026 | [Wave Life Sciences, Inc. earnings report](https://sec-api.dev/companies/wve/catalysts) | WVE |  | completed | "Wave expects to report its final and complete fourth-quarter and full-year 2025 financial results in late February 2026, and the actual results could be different from these preliminary, unaudited financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312526009784/d45710dex991.htm)) |
| January 12, 2026 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "The actual amount of stock-based compensation, restructuring and transaction-related costs for the full year 2026 could have a material impact on GAAP reported results for the guidance period." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326000213/exh_991.htm)) |
| January 12, 2026 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta will report its final and complete fourth quarter and full-year 2025 financial results in late February 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526010116/srpt-ex99_1.htm)) |
| January 12, 2026 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "NEW YORK, January 12, 2026 (GLOBE NEWSWIRE) - Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced preliminary, unaudited fourth quarter and full year 2025 financial results and provided additional business updates ahead of its presentation at the 44th Annual J.P. Morgan Healthcare conference." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526010486/sndx-ex99_1.htm)) |
| January 12, 2026 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "BioMarin expects to report its results for the fourth quarter and full year 2025 in February 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/d93149dex991.htm)) |
| January 12, 2026 | [Vir Biotechnology, Inc. earnings report](https://sec-api.dev/companies/vir/catalysts) | VIR |  | completed | "The Company expects to report its final and complete fourth quarter and full-year 2025 financial results in late February 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1706431/000162828026001768/a2026-01x12_8xkxjpmpressre.htm)) |
| January 12, 2026 | [MAXCYTE, INC. earnings report](https://sec-api.dev/companies/mxct/catalysts) | MXCT |  | completed | "MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1287098/000110465926002901/mxct-20260112xex99d1.htm)) |
| January 12, 2026 | [Tab-cel (tabelecleucel) complete response letter (CRL)](https://sec-api.dev/pdufa/tabelecleucel) | ATRA | relapsed or refractory EBV+ PTLD | completed, complete response letter | "Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257dex991.htm)) |
| January 12, 2026 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "The Company expects to issue financial guidance for fiscal year 2026, including details on previously announced planned expense reductions, and full financial results for the fourth quarter and fiscal year 2025, in February 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526009791/rare-ex99_1.htm)) |
| January 12, 2026 | [Cerezyme (imiglucerase) label expansion decision](https://sec-api.dev/pdufa/imiglucerase) | SNY |  | completed, approved | "BLA020367 SUPPL-123 (Efficacy): submission_status AP, submission_status_date 20260112, review_priority STANDARD; sponsor_name GENZYME; product CEREZYME (IMIGLUCERASE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA020367%22)) |
| January 12, 2026 | [Retevmo (selpercatinib) primary completion](https://sec-api.dev/pdufa/selpercatinib) | LLY | Carcinoma, Non-Small-Cell Lung | completed | "NCT04819100 (A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04819100)) |
| January 12, 2026 | [WEZLANA® (ustekinumab) primary completion](https://sec-api.dev/pdufa/ustekinumab) | JNJ | Arthritis, Juvenile | completed | "NCT05083182 (A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05083182)) |
| January 12, 2026 | [Azetukalner primary completion](https://sec-api.dev/pdufa/azetukalner) | XENE | Focal Onset Seizures | completed | "NCT05614063 (A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Xenon Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05614063)) |
| January 12, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-small Cell Lung Cancer | completed | "NCT05925530 (Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05925530)) |
| January 12, 2026 | [Pf-07220060 cdk4 inhibitor primary completion](https://sec-api.dev/pdufa/pf-07220060-cdk4-inhibitor) | PFE | Advanced or Metastatic Breast Cancer | completed | "NCT06105632 (A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06105632)) |
| January 12, 2026 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Myasthenia Gravis, Ocular | completed | "NCT06558279 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06558279)) |
| January 12, 2026 | [LY3848575 primary completion](https://sec-api.dev/pdufa/ly3848575) | LLY | Neuropathic Pain; Distal Sensory Polyneuropathy | completed | "NCT06568042 (Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568042)) |
| January 12, 2026 | [TTI-0102 primary completion](https://sec-api.dev/pdufa/tti-0102) | TTIPF |  | completed | "NCT06644534 (A Study to Assess TTI-0102 vs Placebo in MELAS Patients): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Thiogenesis Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06644534)) |
| January 12, 2026 | [Tonlamarsen primary completion](https://sec-api.dev/pdufa/tonlamarsen) | KARD | Hypertension | completed | "NCT06864104 (A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Kardigan, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06864104)) |
| January 12, 2026 | [Nvx-cov2705 primary completion](https://sec-api.dev/pdufa/nvx-cov2705) | SNY | COVID-19; SARS-CoV-2 Infection | completed | "NCT07079670 (Safety and Immunogenicity of NVX-CoV2705): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07079670)) |
| January 13, 2026 | [ZYCUBO (CUTX-101) FDA approval](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease in pediatric patients | completed, approved | "Miami, FL - January 13, 2026 - Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has approved ZYCUBO® (copper histidinate, formerly known as CUTX-101) for the treatment of Menkes disease in pediatric patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465926003121/fbio-20260113xex99d1.htm)) |
| January 13, 2026 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Announces Preliminary 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000114036126001060/ef20062769_ex99-1.htm)) |
| January 13, 2026 | [Sanofi PDUFA date](https://sec-api.dev/companies/sny/catalysts) | SNY |  | scheduled | "The target action date for the FDA decision is January 13, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm)) |
| January 13, 2026 | [FILSPARI (sparsentan) PDUFA date](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | scheduled | "•The Company's PDUFA target action date for its sNDA seeking full approval for FILSPARI in FSGS is January 13, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/aex991_2025q4xearningsprex.htm)) |
| January 13, 2026 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "(January 13, 2026) - Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226001959/ex99-1.htm)) |
| January 14, 2026 | [ZYCUBO (CUTX-101) PDUFA date](https://sec-api.dev/pdufa/cutx-101) | FBIO |  | completed, approved | "In December 2025, we announced the FDA accepted the resubmission of the NDA for CUTX-101 as a Class 1 resubmission with a new PDUFA target action date of January 14, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465926061233/fbio-20260331x10q.htm)) |
| January 14, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Hodgkin Lymphoma | completed | "NCT02684292 (Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02684292)) |
| January 14, 2026 | [Zanamivir primary completion](https://sec-api.dev/pdufa/zanamivir) | GSK | Influenza, Human; Arthralgia | completed | "NCT04494412 (An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-14 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04494412)) |
| January 14, 2026 | [Lebrikizumab primary completion](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Dermatitis; Eczema | completed | "NCT05559359 (A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-14 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05559359)) |
| January 14, 2026 | [Qtorin 3.9% rapamycin anhydrous gel primary completion](https://sec-api.dev/pdufa/qtorin-3-9-rapamycin-gel) | PVLA | Microcystic Lymphatic Malformation | completed | "NCT06239480 (SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-14 (ACTUAL); Lead Sponsor Palvella Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06239480)) |
| January 15, 2026 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "CULVER CITY, Calif., Jan. 15, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary select operational results for the fiscal quarter and full year ending December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/ibrx-20261158xkexhibit991.htm)) |
| January 15, 2026 | [BB2121 primary completion](https://sec-api.dev/pdufa/bb2121) | BMY | Multiple Myeloma | completed | "NCT03601078 (An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-15 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03601078)) |
| January 15, 2026 | [Gsk3511294 (depemokimab) topline data readout](https://sec-api.dev/pdufa/gsk3511294-depemokimab) | GSK | Asthma | completed | "NCT05243680 (An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-19 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-01-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05243680?tab=results)) |
| January 2026 | [Rabies vaccine (serum-free vero cell), freeze-dried primary completion](https://sec-api.dev/pdufa/rabies-vaccine-serum-free-vero-cell-freeze-dried) | SVA | Rabies | delayed | "NCT07055880 (Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2026-01-15 (ESTIMATED); Lead Sponsor Sinovac Biotech Co., Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07055880)) |
| January 16, 2026 | [DBV Technologies S.A. topline data readout](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed, positive | "On January 16, 2026, the Company announced additional gross proceeds of $195 million (€166.7 million at the exchange rate of 1 EUR = $1.17) resulting from the full exercise of the ABSA Warrants and BS Warrants, following the announcement of the positive VITESSE Topline Results on December 16, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/dbvt-20251231.htm)) |
| January 16, 2026 | [Implanon (etonogestrel) label expansion decision](https://sec-api.dev/pdufa/etonogestrel) | OGN |  | completed, approved | "NDA021529 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20260116, review_priority STANDARD; sponsor_name ORGANON; product IMPLANON (ETONOGESTREL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021529%22)) |
| January 16, 2026 | [Camzyos® (mavacamten) primary completion](https://sec-api.dev/pdufa/mavacamten) | BMY |  | completed | "NCT03723655 (A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-01-16 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03723655)) |
| January 16, 2026 | [MRTX849 primary completion](https://sec-api.dev/pdufa/mrtx849) | BMY | Advanced Colorectal Cancer; Metastatic Colorectal Cancer | completed | "NCT04793958 (Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-16 (ACTUAL); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04793958)) |
| January 16, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight | completed | "NCT06643728 (A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-16 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06643728)) |
| January 16, 2026 | [Zulresso (brexanolone) primary completion](https://sec-api.dev/pdufa/brexanolone) | LPCN | Depression, Postpartum; Depression, Post-Partum; Postpartum Depression (PPD) | completed | "NCT06979544 (A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-16 (ACTUAL); Lead Sponsor Lipocine Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979544)) |
| January 19, 2026 | [MRNA-1647 primary completion](https://sec-api.dev/pdufa/mrna-1647) | MRNA | Cytomegalovirus Infection | completed | "NCT04975893 (A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-19 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04975893)) |
| January 19, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT05158387 (Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-19 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05158387)) |
| January 19, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT05166889 (Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-19 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05166889)) |
| January 20, 2026 | [FMXIN002 interim data readout](https://sec-api.dev/pdufa/ns002) | NSRX |  | completed, positive | "AVIV, Israel, January 20, 2026 -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced positive interim results from its Phase 2 clinical study of NS002, the Company's investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2029039/000149315226002755/ex99-1.htm)) |
| January 20, 2026 | [IGALMI® (dexmedetomidine) NDA/BLA submission](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed | "On January 20, 2026, we announced we submitted a supplemental New Drug Application, or sNDA, to the FDA for IGALMI® in the at-home use setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm)) |
| January 20, 2026 | [ROCKWELL MEDICAL, INC. earnings report](https://sec-api.dev/companies/rmti/catalysts) | RMTI |  | completed | "Rockwell Medical Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1041024/000162828026002478/a2025q4fy25prereleasepr.htm)) |
| January 20, 2026 | [TAK-881 primary completion](https://sec-api.dev/pdufa/tak-881) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05755035 (A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-01-20 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-09-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05755035)) |
| January 20, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Overweight; Obesity | completed | "NCT06047548 (A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-20 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06047548)) |
| January 20, 2026 | [Yellow fever vaccine (live) primary completion](https://sec-api.dev/pdufa/yellow-fever-vaccine-live) | SNY | Yellow Fever Immunization | completed | "NCT07002060 (Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-20 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07002060)) |
| January 21, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed | "NCT04210115 (Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04210115)) |
| January 21, 2026 | [Verquvo (vericiguat) label expansion decision](https://sec-api.dev/pdufa/vericiguat) | MRK |  | completed, approved | "NDA214377 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20260121, review_priority STANDARD; sponsor_name MSD; product VERQUVO (VERICIGUAT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214377%22)) |
| January 22, 2026 | [ABBOTT LABORATORIES earnings report](https://sec-api.dev/companies/abt/catalysts) | ABT |  | completed | "ABBOTT PARK, Ill., Jan. 22, 2026 — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1800/000162828026002982/abt-2025q4xexhibitx991.htm)) |
| January 22, 2026 | [Treatment a : budesonide, glycopyrronium, and formoterol fumarate primary completion](https://sec-api.dev/pdufa/treatment-a-budesonide-glycopyrronium-and-formoterol) | AZN | Chronic Obstructive Pulmonary Disease | completed | "NCT06067828 (A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-22 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06067828)) |
| January 22, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Diabetes Type 2 | completed | "NCT06354660 (Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-22 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06354660)) |
| January 22, 2026 | [Csu lower dose treatment primary completion](https://sec-api.dev/pdufa/csu-lower) | IFRX | Chronic Urticaria, Idiopathic; Hidradenitis; Hidradenitis Suppurativa | withdrawn | "NCT06555328 (Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-01-22 (ACTUAL); Lead Sponsor InflaRx GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06555328)) |
| January 23, 2026 | [Urcosimod FDA approval](https://sec-api.dev/pdufa/urcosimod) | OKYO |  | completed, approved | "January 23, 2026, we announced that the FDA approved compassionate use of urcosimod (0.05%) for treatment of neuropathic corneal pain." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1849296/000149315226006946/form424b5.htm)) |
| January 23, 2026 | [Afrezza (insulin recombinant human) label expansion decision](https://sec-api.dev/pdufa/insulin-recombinant-human) | MNKD |  | completed, approved | "BLA022472 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20260123, review_priority STANDARD; sponsor_name MANNKIND; product AFREZZA (INSULIN RECOMBINANT HUMAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA022472%22)) |
| January 23, 2026 | [Brentuximab vedotin primary completion](https://sec-api.dev/pdufa/brentuximab-vedotin) | PFE | Diffuse Large B-cell Lymphoma | completed | "NCT04404283 (Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-23 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04404283)) |
| January 23, 2026 | [Dtg/3tc primary completion](https://sec-api.dev/pdufa/dtg-3tc) | GSK | HIV; HIV Infections | completed | "NCT05911360 (A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-23 (ACTUAL); Lead Sponsor ViiV Healthcare; Results First Posted 2026-05-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05911360)) |
| January 23, 2026 | [PRT3789 primary completion](https://sec-api.dev/pdufa/prt3789) | PRLD | Advanced Solid Tumor; Esophageal Cancer; Metastatic Solid Tumor | withdrawn | "NCT06682806 (A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-01-23 (ACTUAL); Lead Sponsor Prelude Therapeutics Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06682806)) |
| January 26, 2026 | [TEZSPIRE® (tezepelumab) trial start](https://sec-api.dev/pdufa/tezepelumab) | GENB |  | completed | "The first patient was dosed in our SOLAIRIA-1 Phase 3 clinical trial on January 26, 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/2100782/000119312526083190/generate_bio_424b4.htm)) |
| January 26, 2026 | [GB-0895 trial start](https://sec-api.dev/pdufa/gb-0895) | GENB |  | completed | "The first patient was dosed in our SOLAIRIA-1 Phase 3 clinical trial on January 26, 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/2100782/000119312526083190/generate_bio_424b4.htm)) |
| January 26, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Bladder Cancer | completed | "NCT03924856 (Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-26 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03924856)) |
| January 26, 2026 | [Elezanumab primary completion](https://sec-api.dev/pdufa/elezanumab) | ABBV | Spinal Cord Injury (SCI) | completed | "NCT04295538 (Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-26 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04295538)) |
| January 27, 2026 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) label expansion decision](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed, approved | "BLA761145 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20260127, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22)) |
| January 27, 2026 | [Noxafil (posaconazole) label expansion decision](https://sec-api.dev/pdufa/posaconazole) | MRK |  | completed, approved | "NDA205596 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20260127, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product NOXAFIL (POSACONAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205596%22)) |
| January 27, 2026 | [Idose Tr (travoprost) label expansion decision](https://sec-api.dev/pdufa/travoprost) | GKOS |  | completed, approved | "NDA218010 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20260127, review_priority STANDARD; sponsor_name GLAUKOS; product IDOSE TR (TRAVOPROST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218010%22)) |
| January 28, 2026 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000013/nrix-20260128xexx991.htm)) |
| January 28, 2026 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326000462/exh_991.htm)) |
| January 28, 2026 | [Ofatumumab approved dose primary completion](https://sec-api.dev/pdufa/ofatumumab-approved-dose) | NVS | Relapsing Multiple Sclerosis (RMS) | completed | "NCT06869785 (Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-28 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06869785)) |
| January 28, 2026 | [Total active prevention fresh toothpaste + colgate total active prevention battery toothbrush primary completion](https://sec-api.dev/pdufa/total-active-prevention-fresh-toothpaste-colgate-total-active-prevention-battery) | CL | Plaque; Gingivitis | completed | "NCT07224828 (The Efficacy of a Battery Toothbrush in the Reduction of Established Plaque and Gingivitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-28 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07224828)) |
| January 28, 2026 | [Nda219398 complete response letter (CRL)](https://sec-api.dev/pdufa/nda219398) | CORT |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219398_20260128.pdf%22)) |
| January 29, 2026 | [Ivonescimab NDA/BLA acceptance](https://sec-api.dev/pdufa/ivonescimab) | SMMT | EGFR-mutated locally advanced or metastatic non-squamous NSCLC | completed | "On January 29, 2026, Summit Therapeutics Inc. (the "Company") issued a press release announcing that the U.S. Food & Drug Administration ("FDA") has accepted for filing the Company's Biologics License Application seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous non-small cell lung cancer post-tyrosine kinase inhibitor therapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000006/smmt-20260129.htm)) |
| January 29, 2026 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | completed | "NCT05153317 (Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-29 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05153317)) |
| January 29, 2026 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06454240 (A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-29 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06454240)) |
| January 30, 2026 | [FAYUVI (rebisufligene etisparvovec) NDA/BLA submission](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE | Sanfilippo syndrome type A | completed | "On January 30, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that that it has resubmitted its Biologics License Application ("BLA") seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA) to the U.S. Food and Drug Administration (the "FDA" or the "Agency")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526030590/rare-20260130.htm)) |
| January 30, 2026 | [AQST-108 complete response letter (CRL)](https://sec-api.dev/pdufa/aqst-108) | AQST |  | completed, complete response letter | "Until profitability is achieved, if at all, additional capital and/or other financing or funding will be required, which could be material, to develop and commercialize our product pipeline, including AQST-108, to fund additional development and commercial activities, and that are required by the FDA for Anaphylm under the CRL issued to the Company on January 30, 2026, and to meet our other cash requirements, including debt service." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm)) |
| January 30, 2026 | [Pharming Group N.V. complete response letter (CRL)](https://sec-api.dev/companies/phar/catalysts) | PHAR |  | completed, complete response letter | "Following the Complete Response Letter (CRL) received on January 30, 2026, and a subsequent Type A meeting with the FDA on March 26, 2026, the resubmission seeks approval of 40 mg and 50 mg twice-daily dosing for pediatric patients weighing 27 kg or more, who represent a meaningful proportion of the identified pediatric patient population." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000031/pharmingannouncesusfdaacce.htm)) |
| January 30, 2026 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (January 30, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm)) |
| January 30, 2026 | [Lifevantage Corp earnings report](https://sec-api.dev/companies/lfvn/catalysts) | LFVN |  | completed | "LifeVantage Announces Financial Results for the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/849146/000162828026005431/earningsrelease_q2fy26.htm)) |
| January 30, 2026 | [Nda219870 complete response letter (CRL)](https://sec-api.dev/pdufa/nda219870) | AQST |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219870_20260130.pdf%22)) |
| January 31, 2026 | [Aquestive Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | scheduled | "The Company is working to understand and resolve the concerns of the FDA prior to the scheduled PDUFA goal date of January 31, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aqst-20260109.htm)) |
| January 31, 2026 | [AQST-108 FDA advisory committee meeting](https://sec-api.dev/pdufa/aqst-108) | AQST |  | scheduled | "Submission Completed NDA Accepted by the FDA Potential Advisory Committee Meeting Q2 2025 Q3 2025 Q4 2025 Q1 2026 PDUFA action date is scheduled for January 31, 2026 Strictly Confidential." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000114036125031374/ef20053945_ex99-1.htm)) |
| January 31, 2026 | [Tempest Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/tpst/catalysts) | TPST |  | completed, positive | "Earlier this year, we announced positive interim data from REDEEM-1, including a 100% complete response ("CR") rate among all six efficacy evaluable patients according to the International Myeloma Working Group ("IMWG") uniform response criteria, as well as a favorable safety profile, as of the January 31, 2026 data cutoff." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1544227/000121390026119910/ea0312128-10q_tempest.htm)) |
| January 31, 2026 | [Anaphylm™ (dibutepinephrine) PDUFA date](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type 1 allergic reactions | completed, complete response letter | "Anaphylm™ (dibutepinephrine) Sublingual Film The Company is in contact with the U.S. Food and Drug Administration (FDA) to gather further information about the deficiencies presently identified by the FDA in the New Drug Application (NDA) for Anaphylm, with the goal of addressing those deficiencies prior to the scheduled PDUFA action date of January 31, 2026, once disclosed to the Company." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aquestivepressrelease-fi.htm)) |
| January 31, 2026 | [Pharming Group N.V. PDUFA date](https://sec-api.dev/companies/phar/catalysts) | PHAR |  | scheduled | "•PDUFA target action date of January 31, 2026" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000043/pharminggroupannouncesusfd.htm)) |
| January 31, 2026 | [Anaphylm™ (dibutepinephrine) NDA/BLA acceptance](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | scheduled | "•FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/q22025-ex991earningsrelease.htm)) |
| January 31, 2026 | [Joenja® (leniolisib) PDUFA date](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, complete response letter | "On October 1, 2025, we announced that the FDA had accepted the sNDA and granted Priority Review of the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000049/a2025q3pressrelease.htm)) |
| January 31, 2026 | [GSK4532990 primary completion](https://sec-api.dev/pdufa/gsk4532990) | GSK | Nonalcoholic Fatty Liver Disease; Non-alcoholic Fatty Liver Disease | completed | "NCT05583344 (Phase 2b Study of GSK4532990 in Adults With NASH): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-31 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05583344)) |

Other months: https://sec-api.dev/fda-calendar/2025-12 , https://sec-api.dev/fda-calendar/2026-02. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates January 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-01

```bibtex
@misc{secapidev_fda_calendar_2026_01_20261116,
  title        = {PDUFA dates January 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-01}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_01_20261116","title":"PDUFA dates January 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-01","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
